TScan Therapeutics

TCRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$22.531 M

$0.35 +7.32%

Close of 22 Sept 2026

Revenue

$10.3M

#3148 by revenue

Earnings

-$129.8M

Loss-making

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#138Cel SciCVM$29.9M
#139Evaxion A/SEVAX$29.5M
#140TScan TherapeuticsTCRX$22.5M
#141Estrella ImmunopharmaESLA$21.1M
#142Jasper TherapeuticsJSPR$20.7M

What if TScan Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$476,105.52

Per share 1,341,898× higher

Bitcoin $1.74T

$27,426.49

Per share 77,301× higher

Nvidia $5.52T

$86,858.83

Per share 244,811× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for TScan Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.